Lit Matters 1: Single vs Dual Steroid Therapy in Septic Shock

Septic shock that remains vasopressor-refractory is the main setting where adjunctive corticosteroids enter the conversation. New comparative-effectiveness data suggest hydrocortisone plus fludrocortisone may outperform hydrocortisone alone, but the ED decision still hinges on timing, boarding, and how much protocol complexity you want to add up front.

Dual Steroids in Septic Shock

• Vasopressor-refractory shock window: Adjunctive steroids matter after adequate perfusion attempts and ongoing vasopressor dependence, not as routine time-zero sepsis therapy; that ED timing distinction is worth hearing in the episode.
• Mineralocorticoid rationale: Fludrocortisone adds mineralocorticoid activity to hydrocortisone, a biologically plausible pairing for septic shock patients whose blood pressure remains stubborn despite vasopressors.
• Large emulation cohort: A Premier database target-trial emulation captured about 88,000 septic shock patients, giving this question a far larger real-world sample than the earlier dual-steroid trials.
• Headline mortality signal: Death or discharge to hospice was lower with combination therapy, roughly 47% versus 51% with hydrocortisone alone, a signal strong enough to keep the question alive.
• Secondary outcome direction: Vasopressor-free days and hospital length both moved in favor of dual therapy, with about a one-day improvement, though residual confounding still limits certainty.
• Practical ED adoption: For frontline emergency care, simplicity still competes with theory: a single inexpensive steroid such as dexamethasone may be the default, while prolonged boarding or escalating pressors may justify more.